PLAINSBORO, N.J.--(BUSINESS WIRE)--Aug. 15, 2001--Integra LifeSciences Holdings Corporation (NASDAQ: IART) announced today that it has scheduled an Investor Forum at the Congress of Neurological Surgeons meeting on Tuesday, October 2, 2001 at 7:30 AM Pacific Time at the Radisson Hotel Harbor View in San Diego, California.
The meeting will be hosted by Stuart Essig and will include an update to the Company's financial guidance for the remainder of 2001 and for the years 2002 and 2003. The Investor Forum will feature presentations by the Company's senior research, sales and marketing personnel concerning new product launches and the product pipeline. A question and answer session will follow.
The Investor Forum is open to the general public and can be accessed live via telephone by dialing 973-633-6740. Investors who wish to attend the Investor Forum in person should send an email to the attention of John Bostjancic (jbostjancic@integra-LS.com) requesting a reservation to attend in person.
Listeners participating via telephone will not be able to ask questions during the question and answer session. A replay of the broadcast will be available through October 16, 2001 by dialing 973-341-3080 (pin code 2772416).
Integra LifeSciences Holdings Corporation develops, manufactures and markets medical devices, implants and biomaterials primarily used in the treatment of cranial and spinal disorders, soft tissue repair and orthopedics.
Integra is a leader in applying the principles of biotechnology to medical devices that improve patients' quality of life. The Company has its corporate headquarters in Plainsboro, New Jersey and has approximately 575 permanent employees.
Statements made in the upcoming Investor Forum may be forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements involve risks and uncertainties that could cause actual results to differ materially from predicted results.
Forward-looking factors that may be discussed include, but are not limited to, expected financial results, new product development, governmental approvals, market potential, and expected sales and potential therapeutic applications of new products.
In addition, the economic, competitive, governmental, technological and other factors identified under the heading "Risk Factors" included in the Business section of Integra's Annual Report on Form 10-K/A for the year ended December 31, 2000 and information contained in subsequent filings with the Securities and Exchange Commission could affect actual results.
|CONTACT:||Integra LifeSciences Holdings Corporation, Plainsboro|
|John B. Henneman, III, 609/936-2481|
|John Bostjancic, 609/936-2239|